Trial reportInternational journal of clinical oncology2026
Preoperative single-dose systemic steroid in major head and neck surgery (J-SUPPORT 2002, PreSte-HN Study): a phase III, placebo-controlled, randomized, double-blind study.
Trial report in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundEnhanced Recovery After Surgery programs have been adopted for head and neck cancer surgery with free tissue transfer reconstruction, but postoperative recovery remains difficult because of the high invasiveness of this procedure. Corticosteroids administered before surgery reduce pain, nausea, and systemic inflammation in other surgical settings, but their benefit in this context is uncertain.
methodsThis phase III, multicenter, randomized, double-blind, placebo-controlled trial was conducted at three tertiary cancer centers in Japan. A total of 180 adults undergoing head and neck cancer surgery with free tissue transfer reconstruction were randomly assigned to receive a single intravenous dose of 8 mg dexamethasone phosphate or placebo before surgery. The primary outcome was postoperative quality of recovery, assessed by total scores on the Japanese version of the Quality of Recovery questionnaire on postoperative days 2 and 4. Secondary outcomes included postoperative pain, nausea, systemic inflammatory markers, postoperative complications, and length of hospital stay.
resultsAmong 178 evaluable patients, postoperative quality of recovery did not differ significantly between the dexamethasone and placebo groups. No significant differences were observed in postoperative pain or nausea. Dexamethasone significantly reduced postoperative serum interleukin-6 and C-reactive protein levels but did not improve patient-reported recovery or shorten hospitalization. Overall postoperative complication rates were similar between the groups.
conclusionsPreoperative dexamethasone reduced systemic inflammation but did not improve postoperative recovery, pain, or nausea after head and neck cancer surgery with free tissue transfer reconstruction. Inflammation control alone may be insufficient to enhance recovery after highly invasive surgery.
Indexed as
Identifiers
42479256What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.